Trials / Recruiting
RecruitingNCT05853367
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-0472 | Oral Administration |
| BIOLOGICAL | Pembrolizumab | IV infusion |
| DRUG | MK-1084 | Oral Administration |
Timeline
- Start date
- 2023-07-06
- Primary completion
- 2028-02-12
- Completion
- 2028-02-12
- First posted
- 2023-05-10
- Last updated
- 2026-03-13
Locations
25 sites across 7 countries: United States, Canada, Chile, Israel, Poland, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05853367. Inclusion in this directory is not an endorsement.